Silence Therapeutics Plc American Depository Share
Symbol: SLN (NASDAQ)
Company Description:
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
- Today's Open: $7.14
- Today's High: $7.889
- Today's Low: $6.886
- Today's Volume: 136.98K
- Yesterday Close: $7.2
- Yesterday High: $7.58
- Yesterday Low: $6.94
- Yesterday Volume: 203.61K
- Last Min Volume: 0
- Last Min High: $7.889
- Last Min Low: $7.456
- Last Min VWAP: $0
- Name: Silence Therapeutics Plc American Depository Share
- Website: https://www.silence-therapeutics.com
- Listed Date: 2020-09-08
- Location: LONDON, X0
- Market Status: Active
- CIK Number: 0001479615
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $349.53M
- Round Lot: 100
- Outstanding Shares: 47.23M
- Asset Type: ADRC
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-23 | 8-K | View |
| 2025-08-14 | 8-K | View |
| 2025-08-07 | 10-Q | View |
| 2025-08-07 | 8-K | View |
| 2025-08-04 | 4 | View |
| 2025-07-31 | 4 | View |
| 2025-07-23 | 4 | View |
| 2025-07-16 | 4 | View |
| 2025-07-10 | 4 | View |
| 2025-06-30 | 4 | View |
| 2025-06-27 | 8-K | View |
| 2025-06-25 | SCHEDULE 13D/A | View |
| 2025-06-25 | 4 | View |
| 2025-06-20 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-05-29 | 4 | View |
| 2025-05-27 | 4 | View |
| 2025-05-21 | 4 | View |
| 2025-05-20 | 4 | View |
| 2025-05-20 | 3 | View |